LP-184 Rationale and design of two phase 3, Randomized, double-blind, placebo-controlled studies of the efficacy and safety of litifilimab in adults with active systemic lupus erythematosus: TOPAZ-1 and TOPAZ-2

• Richard A Furie,
• Kenneth Kalunian,
• Maria Dall’Era,
• Eric F Morand,
• Puja Joshi,
• Ting Wang,
• Xing Wei,
• Catherine Barbey,
• Ronald FVan Vollenhoven,
• Stacey Goode-sellers,
• George Kong,
• Youmna Lahoud

Affiliations

Richard A Furie

2Division of Rheumatology, Northwell Health, Great Neck, NY, USA

Kenneth Kalunian

4Division of Rheumatology, Allergy and Immunology, University of California San Diego, CA, USA

Maria Dall’Era

5Division of Rheumatology, University of California San Francisco, CA, USA

Eric F Morand

3School of Clinical Sciences, Monash University, Victoria, Australia

Puja Joshi

7MS Immunology Clinical Development, Biogen, Cambridge, MA, USA

Ting Wang

8Biostatistics, Biogen, Cambridge, MA, USA

Xing Wei

8Biostatistics, Biogen, Cambridge, MA, USA

Catherine Barbey

10MS-Immunology Development Unit, Biogen, Baar, Switzerland

Ronald FVan Vollenhoven

1Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centers, Amsterdam, Netherlands

Stacey Goode-sellers

6Research and Development, Biogen, Cambridge, MA, USA

George Kong

8Biostatistics, Biogen, Cambridge, MA, USA

Youmna Lahoud

9MS-Immunology Development Unit, Biogen, Cambridge, MA, USA